Clinical characteristics
| Characteristic . | No. (%) . | Median (range) . |
|---|---|---|
| Total cohort | 240 | |
| Age at transplant, y | 59 (19-74) | |
| Sex | ||
| Female | 68 (28) | |
| Male | 172 (72) | |
| WHO classification | ||
| 0 | 24 (10) | |
| 1 | 119 (50) | |
| 2 | 97 (40) | |
| Bone marrow blasts, % | 5 (0-19) | |
| Circulating blasts, % | 0 (0-19) | |
| Hemoglobin, g/dL | 10 (6-16) | |
| Platelets, × 109/L | 78 (1-737) | |
| Leukocytes, × 109/L | 11.0 (0.1-82.6) | |
| Neutrophils, × 109/L | 5.6 (0.1-59.8) | |
| Transfusion before transplant | 122 (51) | |
| Time from diagnosis to transplant, y | 0.7 (0.01-9.2) | |
| Donor relation | ||
| Matched related | 50 (21) | |
| Matched unrelated | 131 (54) | |
| Mismatched related | 7 (3) | |
| Mismatched unrelated | 52 (22) | |
| Conditioning intensity | ||
| Myeloablative | 106 (44) | |
| Reduced | 134 (56) | |
| Peripheral blood graft | 224 (93) | |
| Pretreatment | ||
| No | 67 (28) | |
| Hydroxyurea | 63 (26) | |
| Hypomethylating agents | 59 (25) | |
| Other | 31 (13) | |
| Unknown | 20 (8) | |
| Comorbidity index* | ||
| 0-1 | 121 (50) | |
| 2-3 | 69 (29) | |
| >3 | 50 (21) | |
| Cytogenetic risk† | ||
| Low | 146 (61) | |
| Intermediate | 36 (15) | |
| High | 29 (12) | |
| Unknown | 29 (12) |
| Characteristic . | No. (%) . | Median (range) . |
|---|---|---|
| Total cohort | 240 | |
| Age at transplant, y | 59 (19-74) | |
| Sex | ||
| Female | 68 (28) | |
| Male | 172 (72) | |
| WHO classification | ||
| 0 | 24 (10) | |
| 1 | 119 (50) | |
| 2 | 97 (40) | |
| Bone marrow blasts, % | 5 (0-19) | |
| Circulating blasts, % | 0 (0-19) | |
| Hemoglobin, g/dL | 10 (6-16) | |
| Platelets, × 109/L | 78 (1-737) | |
| Leukocytes, × 109/L | 11.0 (0.1-82.6) | |
| Neutrophils, × 109/L | 5.6 (0.1-59.8) | |
| Transfusion before transplant | 122 (51) | |
| Time from diagnosis to transplant, y | 0.7 (0.01-9.2) | |
| Donor relation | ||
| Matched related | 50 (21) | |
| Matched unrelated | 131 (54) | |
| Mismatched related | 7 (3) | |
| Mismatched unrelated | 52 (22) | |
| Conditioning intensity | ||
| Myeloablative | 106 (44) | |
| Reduced | 134 (56) | |
| Peripheral blood graft | 224 (93) | |
| Pretreatment | ||
| No | 67 (28) | |
| Hydroxyurea | 63 (26) | |
| Hypomethylating agents | 59 (25) | |
| Other | 31 (13) | |
| Unknown | 20 (8) | |
| Comorbidity index* | ||
| 0-1 | 121 (50) | |
| 2-3 | 69 (29) | |
| >3 | 50 (21) | |
| Cytogenetic risk† | ||
| Low | 146 (61) | |
| Intermediate | 36 (15) | |
| High | 29 (12) | |
| Unknown | 29 (12) |